ecteinascidin 743 has been researched along with Sarcoma in 191 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 42 (21.99) | 29.6817 |
| 2010's | 111 (58.12) | 24.3611 |
| 2020's | 38 (19.90) | 2.80 |
| Authors | Studies |
|---|---|
| Carrabotta, M; De Feo, A; Donati, DM; Durante, G; Giusti, V; Laginestra, MA; Landuzzi, L; Lollini, PL; Manara, MC; Mancarella, C; Palmerini, E; Parra, A; Pasello, M; Righi, A; Ruzzi, F; Scotlandi, K; Toracchio, L | 1 |
| Albert, S; Bessede, A; Blay, JY; Brahmi, M; Chakiba, C; Cousin, S; Croce, S; Floquet, A; Giraud, A; Guégan, JP; Italiano, A; Kind, M; Mathoulin-Pelissier, S; Perret, R; Pulido, M; Ray-Coquard, I; Toulmonde, M; Toulza, E | 1 |
| Bagué, S; Cerdà Serdà, P; López-Pousa, A; Moreno, ME; Orellana, R; Riba, M; Sebio, A; Terés, R | 1 |
| Coukos, G; Digklia, A; Homicsko, K | 1 |
| Grimison, P; King, D; Thomson, K; Zhou, DD | 1 |
| Schöffski, P | 1 |
| Cao, D; Gao, Z; Lin, C; Lin, Y; Liu, H; Liu, SL; Luo, L; Ma, W; Shi, Y; Wang, J; Wang, P; Wang, W; Xiang, Q; Xu, W; Zeng, Z; Zhao, Y | 1 |
| Casali, PG; Celant, S; Comandone, A; Di Segni, S; Napolitano, A; Olimpieri, PP; Russo, P; Sanfilippo, R; Vincenzi, B | 1 |
| Grignani, G; Hindi, N; Ibrahim, T; Le Cesne, A; Martín-Broto, J; Merlini, A | 1 |
| Grignani, G; Le Cesne, A; Martín-Broto, J | 2 |
| Le Cesne, A | 3 |
| Aubry, S; Chaigneau, L; Charon Barra, C; Hervieu, A; Isambert, N; Jary, M; Kalbacher, E; Meynard, G; Nerich, V; Neumann, F | 1 |
| Aquilano, M; Becherini, C; Campanacci, DA; Francolini, G; Greto, D; Livi, L; Loi, M; Mangoni, M; Melica, ME; Salvatore, G; Salvestrini, V; Santini, C; Sottili, M; Talamonti, C; Valzano, M | 1 |
| Assi, T; Cesne, AL | 2 |
| Abe, K; Furukawa, T; Iwata, S; Maejima, A; Saito, Y; Shimoi, T; Udagawa, R; Wakao, F; Yonemori, K | 1 |
| Ae, K; Fukuda, N; Hayakawa, K; Hayashi, N; Matsumoto, S; Minami, Y; Nakano, K; Ohmoto, A; Oki, R; Ono, M; Saito, M; Sato, Y; Suto, H; Takahashi, S; Tanizawa, T; Tomomatsu, J; Udagawa, S; Urasaki, T; Wang, X; Yunokawa, M | 1 |
| Alvarez, R; Blay, JY; Casali, PG; Cruz Jurado, J; Dei Tos, AP; Fabbroni, C; Gronchi, A; Gutierrez, A; Hindi, N; Italiano, A; Lopez-Pousa, A; Martin-Broto, J; Morosi, C; Pérez Aguiar, JL; Ranchere-Vince, D; Rincón-Perez, I; Romagosa, C; Romero, J; Sanfilippo, R; Sangalli, C; Sunyach, MP | 1 |
| Meeus, P; Ray-Coquard, I; Turinetto, M | 1 |
| Assi, T; Bahleda, R; Faron, M; Hénon, C; Honoré, C; Le Cesne, A; Le Péchoux, C; Lévy, A; Ngo, C; Verret, B | 1 |
| Decoupigny, E; Isambert, N; Le Cesne, A; Penel, N; Taieb, S; Tresch-Bruneel, E | 1 |
| Jones, RL | 1 |
| Hindi, N; Martin-Broto, J; Moura, DS | 1 |
| Hayakawa, K; Iwata, S; Kobayashi, H; Oka, H; Tanaka, S; Ueda, T; Wakamatsu, T; Wasa, J; Yonemoto, T | 1 |
| Alastuey, I; Alvarez, R; Alvarez-Gonzalez, A; Belinchon, B; Blay, JY; Coindre, JM; Cruz-Jurado, J; Dei Tos, AP; Dolado, MC; Gatti, M; Grignani, G; Gronchi, A; Gutierrez, A; Hindi, N; Isern-Verdum, J; Italiano, A; Lopez-Pousa, A; Luna, P; Martin-Broto, J; Martinez-Serra, J; Morosi, C; Moura, DS; Peinado-Serrano, J; Redondo, A; Rincon-Pérez, I; Romagosa, C; Romero, J; Sanchez-Bustos, P; Sargos, P; Sunyach, MP | 1 |
| Araki, N; Endo, M; Goda, K; Hiraga, H; Hiruma, T; Kawai, A; Kunisada, T; Matsumine, A; Morioka, H; Sugiura, H; Takahashi, M; Takahashi, S; Ueda, T; Yonemoto, T | 1 |
| Corona, G; Di Gregorio, E; Miolo, G; Steffan, A | 1 |
| Corbellari, R; De Luca, R; Nadal, L; Neri, D; Villa, A | 1 |
| Jones, RL; Martín-Broto, J; Reichardt, P; Stacchiotti, S | 1 |
| Arndt, K; Bornhäuser, M; Chemnitz, JM; Freitag, J; Grünwald, V; Hentschel, L; Hornemann, B; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Pelzer, U; Richter, S; Schilling, A; Schuler, MK; Schuler, U | 1 |
| Blay, JY; de Sande González, LM; Kasper, B; Le Cesne, A; Martin-Broto, J | 1 |
| Asanuma, K; Hagi, T; Nakamura, T; Sudo, A | 1 |
| Broto, JM; Jones, RL | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonastre, J; Bouvet, N; Chaigneau, L; Chevreau, C; Cupissol, D; Delcambre, C; Foulon, S; Fraslin, A; Guillemet, C; Haddag, L; Isambert, N; Italiano, A; Kapso, R; Le Cesne, A; Mir, O; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Rios, M; Salas, S | 1 |
| Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M | 1 |
| Schuetze, S | 1 |
| Bongiovanni, A; Brandolini, F; Calpona, S; Casadei, R; Cavaliere, D; Cocchi, C; De Vita, A; Debonis, SA; Di Menna, G; Ercolani, G; Fabbri, F; Farnedi, A; Fausti, V; Gurrieri, L; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Pieri, F; Recine, F; Riva, N; Spadazzi, C; Vanni, S | 1 |
| Agra-Pujol, C; Alvarez, R; Alvarez-Alegret, R; Bagué, S; Castilla-Ramirez, C; Cordero Varela, JA; de Juan, A; Dopazo, J; Fiaño-Valverde, MC; Gutierrez, A; Hernández Barceló, JE; Hernandez-Leon, CN; Hindi, N; Izquierdo, F; Lacerenza, S; Lavernia, J; Lopez-Alvarez, M; Martín-Broto, J; Martin-Davila, F; Martinez-Trufero, J; Mayodormo-Aranda, E; Moura, DS; Ortega-Medina, L; Peña-Chilet, M; Ramos, R; Romagosa, C; Rubio-Casadevall, J; Valverde, C; Vaz Salgado, MA; Vicioso, L | 1 |
| Kawai, A; Kondo, T; Nakatani, F; Noguchi, R; Ohtori, S; Ono, T; Sei, A; Sin, Y; Sugaya, J; Takeshita, F; Tsuchiya, R; Yoshida, A; Yoshimatsu, Y | 1 |
| Blažičević, K; Golčić, M; Herceg, D; Ladenhauser, T; Majnarić, T; Simetić, L | 1 |
| Algéo, MP; Chaire, V; Italiano, A; Laroche, A; Le Loarer, F; Lucchesi, C; Rey, C; Tran, K | 1 |
| Aglietta, M; Aliberti, S; Basiricò, M; Benassi, MS; Boccone, P; Canta, M; Capozzi, F; Chiabotto, G; Chiorino, G; D'Ambrosio, L; Dell'Aglio, C; Galizia, D; Gammaitoni, L; Grignani, G; Lorenzato, A; Miano, S; Napione, L; Palesandro, E; Pasini, B; Pignochino, Y; Sangiolo, D; Vignolo Lutati, F | 1 |
| Araki, N; Hiraga, H; Hiruma, T; Kawai, A; Kunisada, T; Matsumine, A; Morioka, H; Shimura, M; Sugiura, H; Takahashi, M; Takahashi, S; Ueda, T; Yonemoto, T | 1 |
| Patel, SR; Ratan, R | 1 |
| Araki, N; Kawai, A; Takahashi, S; Ueda, T; Yonemori, K | 1 |
| Bornhäuser, M; Ehninger, G; Hentschel, L; Richter, S; Schuler, M | 1 |
| Benson, C; Brodowicz, T; Buonadonna, A; Casanova, J; Kasper, B; López Pousa, A; Mazzeo, F; Penel, N | 1 |
| Sleijfer, S; Vos, M | 1 |
| Amadori, D; Bongiovanni, A; Casadei, R; De Vita, A; Fausti, V; Ibrahim, T; Liverani, C; Mercatali, L; Miserocchi, G; Pieri, F; Recine, F; Riva, N; Spadazzi, C | 1 |
| Armento, G; Badalamenti, G; Catania, G; Incorvaia, L; Maltese, G; Napolitano, A; Santini, D; Silletta, M; Spalato Ceruso, M; Tonini, G; Valeri, S; Vincenzi, B | 1 |
| Berruti, A; Bianchi, S; Consoli, F; Cosentini, D; Ferrari, VD; Grisanti, S; Lazzari, B; Roca, E; Tovazzi, V | 1 |
| Collin, F; Gronchi, A; Italiano, A; Litière, S; Pourquier, P; Touati, N | 1 |
| Aglietta, M; Aliberti, S; Bardelli, A; Bartolini, A; Bertulli, R; Boccone, P; Chiabotto, G; D'Ambrosio, L; D'Incalci, M; Dei Tos, AP; Ferrari, S; Grignani, G; Marchesi, E; Miano, S; Novara, L; Palmerini, E; Piana, R; Picci, P; Pignochino, Y; Pisacane, A; Sangiolo, D; Stacchiotti, S; Tolomeo, F; Zucchetti, M | 1 |
| Nacev, BA; Tap, WD | 1 |
| Garcia Del Muro, X; Ibrahim, T; Jones, RL; Le Cesne, A; Menge, F | 1 |
| Esser, M; Fritz, J; Horger, M; Kloth, C; Kopp, HG; Reinert, CP; Thaiss, WM | 1 |
| Merimsky, O; Shamai, S | 1 |
| Davidson, D; Doherty, GJ; Hatcher, HM; Wong, HH | 1 |
| Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N | 1 |
| Baldi, GG; Gronchi, A; Suarez-Kelly, LP | 1 |
| Iwasaki, J; Komori, T; Matsuo, K; Nagase, H; Nakagawa, F; Uchida, J; Uto, Y | 1 |
| Constantinidou, A; Jones, RL; Loggers, E; Pollack, S; Rodler, E | 1 |
| Papaioannou, D; Rafia, R; Simpson, E; Stevenson, M | 1 |
| Blay, JY | 4 |
| Casali, PG; Sanfilippo, R | 1 |
| Reichardt, P | 2 |
| Ahrens, M; Bauer, S; Grabellus, F; Hoiczyk, M; Podleska, L; Pöttgen, C; Schuler, M; Schwindenhammer, B; Taeger, G | 1 |
| Brodowicz, T; Eisterer, W; Köstler, WJ; Kühr, T; Lamm, W; Lindorfer, A; Ploner, F; Schur, S; Szkandera, J; Tinchon, C | 1 |
| Brodowicz, T; Hoetzenecker, K; Klepetko, W; Köstler, WJ; Lamm, W; Nemecek, E; Schur, S; Schwameis, K; Windhager, R | 1 |
| Judson, I; Martin-Liberal, J | 1 |
| Manson, SC; Penel, N; Powell, S; Sharma, S; Takyar, S | 1 |
| Blay, JY; Cesne, AL; Chawla, SP; Demetri, GD; Grosso, F; Judson, I; Maki, R; Mehren, MV; Nieto, A; Schuetze, S; Tanovic, A | 1 |
| Bétrian, S; Chatelut, E; Chevreau, C; Hennebelle, I; Laurenty, AP; Le Guellec, C; Le Guellec, S; Thomas, F | 1 |
| Alam, S; Davidson, D; Earl, HM; Gounaris, I; Hatcher, HM; Horan, G; Sherbourne, K; Zaki, KA | 1 |
| Alfaro, V; Blay, JY; Chawla, SP; Hendifar, A; Hohenberger, P; Lardelli, P; Leahy, MG; Nguyen, BB; Nieto, A; Patel, SR; Penel, N; Piperno-Neumann, S; Santoro, A; Staddon, AP | 1 |
| Ando, M; Kakunaga, S; Kawai, A; Sugiura, H; Ueda, T; Yamada, K; Yonemori, K | 1 |
| Elias, A; Gajdos, C; Lopez, JP | 1 |
| Cornillie, J; Hompes, D; Li, H; Schöffski, P; Wozniak, A | 1 |
| Cuesta, M; Guix, M; Hernández-Pastor, LJ; Lavernia, J; Villa, G | 1 |
| Brodowicz, T | 1 |
| Fernandez Teruel, C; Moe, MM; Soto-Matos, A | 1 |
| De Sarro, G; Di Paola, ED; Gallelli, L; Leporini, C; Lucia, M; Patanè, M; Rende, P; Rossi, M; Russo, E; Saullo, F; Toscano, R | 1 |
| Elowsson, C; Krarup-Hansen, A; Mouritsen, LS; Safwat, A; Schack, LH | 1 |
| Bompas, E; Clisant, S; Guillemet, C; Italiano, A; Maynou, C; Penel, N; Peugniez, C; Piperno-Neumann, S; Ryckewaert, T; Saada-Bouzid, E; Taieb, S; Thyss, A; Tresch, E | 1 |
| Hohenberger, P; Kasper, B; Mathew, M; Pink, D; Rauch, G; Reichardt, P; Sommer, M | 1 |
| Bertucci, F; Chaire, V; Italiano, A; Laroche-Clary, A; Le Morvan, V; Neuville, A; Pourquier, P; Salas, S; Sanfilippo, R | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Chevreau, C; Clisant, S; Delcambre, C; Domont, J; Isambert, N; Italiano, A; Le Cesne, A; Mir, O; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Ryckewaert, T; Saada-Bouzid, E; Tresch-Bruneel, E; Valentin, T | 1 |
| Jones, RL; Loggers, ET; Petek, BJ; Pollack, SM | 1 |
| Bertucci, F; Bompas, E; Bui Nguyen, B; Chaigneau, L; Chevreau, C; Cousin, P; Delcambre, C; Duffaud, F; Even, C; Guillemet, C; Kurtz, JE; Le Cesne, A; Le Maignan, C; Linassier, C; Olivier, T; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Rios, M; Yves Blay, J | 1 |
| Cable, MG; Randall, RL | 1 |
| Jahn, F; Jordan, B; Jordan, K; Kegel, T; Müller-Tidow, C; Rüssel, J | 1 |
| Araki, N; Hasegawa, T; Hiraga, H; Hiruma, T; Kawai, A; Kunisada, T; Matsumine, A; Morioka, H; Sugiura, H; Takahashi, M; Takahashi, S; Tanase, T; Ueda, T; Yonemoto, T | 1 |
| Blay, JY; Bui-Nguyen, B; Butrynski, JE; Collin, F; Isambert, N; Kerst, JM; Litière, S; Marréaud, S; Milhem, M; Penel, N; Reyners, AK; van der Graaf, WT | 1 |
| Le Cesne, A; Reichardt, P | 1 |
| Grignani, G; Martín-Broto, J; Reichardt, P; Schuler, M | 1 |
| Badalamenti, G; Cerbone, L; De Lisi, D; Frezza, AM; Maltese, G; Santini, D; Silletta, M; Spalato Ceruso, M; Stumbo, L; Tonini, G; Vincenzi, B | 1 |
| Alemany, R; Calabuig-Fariñas, S; Felipe-Abrio, I; López-Guerrero, JA; Martín-Broto, J; Martinez-Font, E; Obrador-Hevia, A; Ramos, R; Serra-Sitjar, M | 1 |
| Ben Mrad, M; Collard, O; Diao, P; Espenel, S; Fournel, P; Langrand-Escure, J; Magné, N; Méry, B; Moriceau, G; Rivoirard, R; Vallard, A; Wang, G | 1 |
| Blay, JY; Bompas, E; Bui-Nguyen, B; Chaigneau, L; Chaltiel, L; Chevreau, C; Cousin, P; Delord, JP; Khalifa, J; Le Cesne, A; Le Guellec, S; Ouali, M; Penel, N; Piperno-Neumann, S; Rios, M | 1 |
| Cousin, S; Penel, N; Peugniez, C | 1 |
| Balzarini, L; Bastoni, S; Bertuzzi, AF; Daolio, P; De Sanctis, R; Lutman, FR; Marchetti, S; Marrari, A; Mussi, C; Quagliuolo, V; Santoro, A | 1 |
| Abdul Razak, AR; Angarita, FA; Blackstein, ME; Cannell, AJ; Dickson, BC | 1 |
| Araki, N; Hiraga, H; Hiruma, T; Kawai, A; Kunisada, T; Matsumine, A; Morioka, H; Sugiura, H; Takahashi, M; Takahashi, S; Ueda, T; Yonemoto, T | 1 |
| Belka, C; Cardoso Martins, AS; Gallmeier, E; Guo, Y; Harnicek, D; Hennel, R; Hiddemann, W; Hucl, T; Issels, RD; Kampmann, E; Kanaar, R; Lauber, K; Lindner, LH; Mansmann, U; Mörtl, S | 1 |
| Asanuma, H; Hasegawa, T; Sugita, S | 1 |
| Carbini, M; Maki, RG; Pang, A | 1 |
| Alemany, R; Alvarez, R; Balaña, C; Carrasco, JA; Cruz, J; Cubedo, R; De Juan, A; de Las Peñas, R; García Del Muro, X; Gutierrez, A; Lopez-Guerrero, JA; López-Martin, JA; Martin-Broto, J; Martinez-Serra, J; Martinez-Trufero, J; Maurel, J; Meana, JA; Pousa, AL; Poveda, A; Ramos, R; Redondo, A; Sala, Á; Sevilla, I; Vaz, Á | 1 |
| Chawla, N; Chawla, SP; Gordon, EM; Sankhala, KK | 1 |
| Azvolinsky, A | 1 |
| De Sanctis, R; Marrari, A; Santoro, A | 1 |
| Baldi, GG; Bertulli, R; Di Donato, S; Dona, M; Fantini, L; Fargnoli, R; Panella, M; Parisi, E; Sbaraglia, M | 1 |
| Bakhshi, S; Rastogi, S | 1 |
| Daupin, J; Debrix, I; Fillon, J; Lotz, JP; Paubel, P; Soares, DG | 1 |
| von Mehren, M; Zijoo, R | 1 |
| Aracil, M; D'Incalci, M; Italiano, A; Kaye, SB; Lorusso, D; Monk, BJ; Tanović, A | 1 |
| Thornton, K | 1 |
| Dumez, H; Jimeno, J; Schöffski, P; Stefan, C; Van Oosterom, AT; Wolter, P; Wozniak, A | 1 |
| Antony, S; Aune, GJ; Bohr, VA; Guirouilh-Barbat, J; Pommier, Y; Sordet, O; Takagi, K | 1 |
| Blay, JY; Buckley, B; Elsayed, YA; Fanucchi, MP; Gilles, L; Le Cesne, A; Lebedinsky, C; Ray-Coquard, I; Samuels, BL; von Mehren, M | 1 |
| Capri, G; Cresta, S; D'Incalci, M; De Braud, F; Feilchenfeldt, JW; Gallerani, E; Gianni, L; Ielmini, N; Jimeno, J; Locatelli, A; Noberasco, C; Perotti, A; Sessa, C; Viganò, L; Zucchetti, M | 1 |
| Amant, F; Coosemans, A; Everaert, E; Renard, V; Vergote, I | 1 |
| Baconnier, M; Blay, JY; Boudou, L; Cassier, PA; Lombard-Bohas, C | 1 |
| Alfaro, V; Blay, JY; Bonvalot, S; Cioffi, A; Domont, J; Le Cesne, A; Lebedinsky, C; Ray-Coquard, I; Santabarbara, P; Terrier, P | 1 |
| Blay, JY; Bui, B; Cassier, P; Dufresne, A; Le Cesne, A; Vanel, D | 1 |
| Cohen, AF; Dubois, EA | 1 |
| Dimitrakopoulou-Strauss, A; Egerer, G; Ho, AD; Kasper, B; Schmitt, T; Wuchter, P | 1 |
| Alberti, L; Blay, JY; Boyle, H; Cassier, P; Chabaud, S; Decouvelaere, AV; Engel, C; Favier, B; Fayette, J; Méeus, P; Pérol, D; Ranchère, D; Ray-Coquard, I; Sunyach, MP; Thiesse, P; Vaz, G | 1 |
| Nystrom, KK; Pick, AM | 1 |
| Carter, NJ; Keam, SJ | 2 |
| Budd, GT; Wesolowski, R | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Casali, PG; D'Incalci, M; Sanfilippo, R | 1 |
| Papaioannou, D; Rafia, R; Simpson, EL; Stevenson, MD | 1 |
| García San Andrés, B; Joensuu, T; Soini, EJO | 1 |
| Balañá, C; Bellmunt, J; Buesa, JM; Casado, A; Ciruelos, E; Cortes-Funes, H; del Muro, JG; Izquierdo, MA; López-Pousa, A; Nieto, A; Paz-Ares, L; Poveda, A; Provencio, M; Rivera-Herrero, F; Tanović, A | 1 |
| Dietrich, S; Egerer, G; Ho, AD; Keller, E; Schmitt, T; Wuchter, P | 1 |
| Blay, JY; Bui, B; Casali, P; Coindre, JM; Italiano, A; Jimeno, J; Judson, I; Laroche, A; Laurand, A; Le Cesne, A; Nieto, A; Pourquier, P; Ray-Coquard, I; Robert, J; Sanfilippo, R; Tercero, JC | 1 |
| Blomqvist, C; Johansson, R; Tarkkanen, M | 1 |
| Blay, JY; Casali, PG; Grosso, F; Jimeno, J; Jones, RL; Le Cesne, A; Maki, RG; Nieto, A; Poveda, A; Rosell, R; Sanfilipio, R; Schöffski, P; Taron, M; Tercero, JC | 1 |
| Chen, QR; Griffin, LB; Grohar, PJ; Helman, LJ; Khan, J; Khanna, C; Pommier, Y; Yeung, C | 1 |
| Al-Muderis, O; Constantinidou, A; Fisher, C; Jones, RL; Judson, IR; Olmos, D; Scurr, M; Thway, K | 1 |
| Bellmunt, J; Cullell-Young, M; Goel, S; Hudes, GR; Kahatt, C; Kantoff, PW; Lardelli, P; Lee, RJ; Lewis, NL; Michaelson, MD; Nieto, A; Pardos, I; Smith, MR; Stein, CA | 1 |
| Movva, S; Verschraegen, C | 1 |
| Adamson, PC; Baker, KS; Baruchel, S; Blaney, SM; Krailo, M; Lee-Scott, M; Pappo, A; Villaluna, D; Wu, B | 1 |
| Cioffi, A; Italiano, A | 1 |
| Batko, S; Benesová, V; Bortlícek, Z; Dreslerová, J; Fínek, J; Kandrnal, V; Kubácková, K; Lazarov, PP; Lysý, M; Ptátková, Z; Vocka, M; Vyzula, R; Zvaríková, M | 1 |
| Cerbone, L; Clement, P; De Wever, I; Dumez, H; Samson, I; Schöffski, P; Stas, M; Wildiers, H; Wolter, P | 1 |
| Alfaro, V; Balaña, C; Blay, JY; Casali, PG; Cresta, S; Demetri, GD; Grosso, F; Lardelli, P; Le Cesne, A; Maki, RG; Nieto, A; Poveda, A; Schöffski, P; Verweij, J | 1 |
| Blay, JY; Casali, P; Cassar, A; Chawla, SP; Cousin, S; Demetri, GD; Gomez, J; Judson, I; Le Cesne, A; Maki, RG; Nieto, A; Penel, N; Pontes, MJ; Rodenhuis, S; Schöffski, P; Schütte, HJ; Verweij, J; von Mehren, M; Zintl, P | 1 |
| Shi, YQ | 1 |
| Aymes, A; Chawla, S; Demetri, GD; Hamm, J; Kaiser, PE; Li, J; Patel, S; Samuels, BL; Schuetze, S; von Mehren, M | 1 |
| Badri, N; Bertucci, F; Blay, JY; Bompas, E; Bui, B; Cassier, P; Chaigneau, L; Coindre, JM; Collard, O; Decanter, G; Derbel, O; Duffaud, F; Isambert, N; Italiano, A; Le Cesne, A; Penel, N; Ray-Coquard, I; Rios, M; Zintl, P | 1 |
| Brain, EG | 1 |
| Demetri, GD | 1 |
| Butkiewicz, L; Demetri, GD; Garcia-Carbonero, R; Guzman, C; Harmon, D; Jimeno, J; Lopez-Lazaro, L; Maki, RG; Puchalski, TA; Ryan, DP; Seiden, MV; Supko, JG | 1 |
| Burton, A | 1 |
| Patel, SR | 1 |
| von Mehren, M | 2 |
| Fondren, G; Hornicek, FJ; Kasanov, J; Morii, T; Shao, L; Weissbach, L | 1 |
| Alexandre, J; Blay, JY; Brain, E; Cvitkovic, E; Jimeno, J; Kahatt, C; Martin, C; Misset, JL; Riofrio, M; Salhi, Y; Taamma, A; Yovine, A | 1 |
| Canniff, J; Demetri, GD; Garcia-Carbonero, R; Gomez, J; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Matulonis, U; Merriam, P; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG | 1 |
| Blay, JY; Bonvalot, S; Evrard, V; Hogendoorn, P; Jimeno, J; Judson, I; Le Cesne, A; Scurr, M; Seynaeve, C; van Glabbeke, M; Verweij, J | 1 |
| Blay, JY; Bonvalot, S; Collin, F; Di Paola, E; Jimeno, J; Judson, I; Le Cesne, A; Lorigan, P; Nielsen, OS; Radford, J; Ray-Coquard, I; Rodenhuis, S; Van Glabbeke, M; Van Oosterom, A; Verweij, J | 1 |
| Carnero, A; Fernández, I; Jimeno, J; Martínez, N; Moneo, V; Navarrete, M; Piris, MA; Sánchez-Beato, M; Tercero, JC | 1 |
| Judson, I; Le Cesne, A; Therasse, P; Van Glabbeke, M; Verweij, J | 1 |
| Verweij, J | 1 |
| Demetri, GD; Garcia-Carbonero, R; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG; Waxman, A | 1 |
| Beijnen, JH; Beumer, JH; Lopez-Lazaro, L; Rademaker-Lakhai, JM; Rosing, H; Schellens, JH | 1 |
| Blay, JY; Fayette, J; Méeus, P; Ray Coquard, I; Sunyach, MP; Thiesse, P | 1 |
| Alberti, L; Blay, JY; Boyle, H; Coquard, IR; Decouvelaere, AV; Fayette, J; Méeus, P; Ranchère, D; Sunyach, MP; Thiesse, P | 1 |
| Bertulli, R; Casali, PG; D'Incalci, M; Dileo, P; Gescher, A; Grosso, F; Jimeno, J; Piovesan, C; Sanfilippo, R; Stacchiotti, S | 1 |
| Blanco-Aparicio, C; Carnero, A; Cigudosa, JC; Fominaya, J; Jimeno, J; Leal, JF; Moneo, V; Piris, MA; Romero, L; Sánchez-Beato, M; Serelde, BG; Tercero, JC | 1 |
| Beldner, M; Kraft, A; Montero, AJ; Skorupa, A | 1 |
| Daniels, S; McTiernan, A; Roylance, R; Seddon, B; Sykes, K; Whelan, J | 1 |
| Clement, P; De Wever, I; Dumez, H; Schöffski, P; Sciot, R; Stefan, C; Wolter, P; Wozniak, A | 1 |
| Brain, E; Cottu, P; Cvitkovic, E; Delaloge, S; Goldwasser, F; Jimeno, J; Marty, M; Misset, JL; Raymond, E; Riofrio, M; Taamma, A; Yovine, A | 1 |
| Bertino, JR; Cordon-Cardo, C; Elisseyeff, Y; Faircloth, G; Jhanwar, S; Jimeno, J; Li, WW; Takahashi, N | 1 |
| Banerjee, D; Bertino, JR; Li, WW; Scotto, KW; Takahashi, N | 1 |
| Biron, P; Blay, JY; Ray-Coquard, I | 1 |
57 review(s) available for ecteinascidin 743 and Sarcoma
| Article | Year |
|---|---|
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Topics: Doxorubicin; Humans; Ifosfamide; Liposarcoma; Sarcoma; Trabectedin | 2022 |
Trabectedin in Cancers: Mechanisms and Clinical Applications.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Dioxoles; Humans; Lung Neoplasms; Sarcoma; Trabectedin; Tumor Microenvironment | 2022 |
A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Quality of Life; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes.
Topics: Aged; Antineoplastic Agents, Alkylating; Dioxoles; Humans; Quality of Life; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Leiomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2023 |
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
Topics: Doxorubicin; Humans; Liposarcoma; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2023 |
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype.
Topics: Animals; Antineoplastic Agents, Alkylating; Humans; International Cooperation; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2020 |
Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Humans; Leiomyosarcoma; Liposarcoma; Quality of Life; Randomized Controlled Trials as Topic; Sarcoma; Trabectedin | 2020 |
Current Reality of Treating Advanced Soft Tissue Sarcoma as Illustrated by Case Studies.
Topics: Aged; Cell Line, Tumor; Chemoradiotherapy; Clinical Trials as Topic; Humans; Male; Middle Aged; Sarcoma; Trabectedin | 2021 |
Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dioxoles; Drug Evaluation, Preclinical; Furans; Humans; Ketones; Molecular Targeted Therapy; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2017 |
Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Furans; Humans; Indazoles; Japan; Ketones; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin | 2017 |
EJC's biennial report on metastatic soft tissue sarcoma: State of the art and future perspectives.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Therapy; Forecasting; Humans; Indazoles; Neoplasm Metastasis; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin | 2018 |
Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Male; Patient Reported Outcome Measures; Quality of Life; Sarcoma; Trabectedin; Young Adult | 2018 |
Making the Best of Available Options for Optimal Sarcoma Treatment.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Clinical Trials as Topic; Disease Management; High-Throughput Nucleotide Sequencing; Humans; Practice Guidelines as Topic; Sarcoma; Trabectedin | 2018 |
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin | 2019 |
Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Drug Discovery; Drugs, Investigational; Furans; Humans; Ketones; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2019 |
The evolution of systemic therapy in sarcoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chordoma; Deoxycytidine; Dermatofibrosarcoma; Dioxoles; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Hemangiosarcoma; Humans; Osteosarcoma; Proteasome Inhibitors; Receptor, IGF Type 1; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2013 |
Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Dioxoles; Disease-Free Survival; Humans; Models, Theoretical; Neoplasm Metastasis; Quality-Adjusted Life Years; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; United Kingdom | 2013 |
Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Dioxoles; Humans; Rhabdomyolysis; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2013 |
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Failure | 2013 |
Trabectedin: novel insights in the treatment of advanced sarcoma.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Drug Therapy, Combination; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2014 |
Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease.
Topics: Antineoplastic Agents; Dioxoles; Doxorubicin; Evidence-Based Medicine; Humans; Ifosfamide; Indazoles; Pyrimidines; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Trabectedin in soft tissue sarcomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Humans; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Humans; Middle Aged; Neoplasm Staging; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Going further in the knowledge of Yondelis®; what's new in clinical trials?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dioxoles; Doxorubicin; Humans; Neoplasm Staging; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Drug Interactions; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2014 |
Trabectedin in soft tissue sarcomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Humans; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2015 |
Trabectedin: Supportive care strategies and safety profile.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2015 |
Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dioxoles; Disease Progression; Drug Administration Schedule; Hematologic Diseases; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Multicenter Studies as Topic; Palliative Care; Patient Selection; Randomized Controlled Trials as Topic; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Translocation, Genetic | 2015 |
Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review.
Topics: Adult; Antineoplastic Agents; Dioxoles; Furans; Humans; Indazoles; Ketones; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Tumor Microenvironment | 2016 |
Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Europe; Germany; Humans; Neutropenia; Randomized Controlled Trials as Topic; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Trabectedin for the treatment of soft tissue sarcomas.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Disease Management; Humans; Ifosfamide; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Efficacy of trabectedin for the treatment of liposarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Dioxoles; Doxorubicin; Female; Genes, BRCA1; Genes, BRCA2; Hereditary Breast and Ovarian Cancer Syndrome; Humans; Ovarian Neoplasms; Polyethylene Glycols; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Chemotherapeutic management of soft tissue sarcoma.
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Dioxoles; Doxorubicin; Humans; Ifosfamide; Neoadjuvant Therapy; Neovascularization, Pathologic; Sarcoma; Tetrahydroisoquinolines; TNF-Related Apoptosis-Inducing Ligand; Trabectedin | 2008 |
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Disease-Free Survival; Humans; Molecular Structure; Neoplasm Invasiveness; Neoplasm Metastasis; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2008 |
Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2009 |
Trabectedin for the management of soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Controlled Clinical Trials as Topic; Dioxoles; DNA Repair; Female; Humans; Liver; Neutropenia; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2009 |
Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Humans; Pharmacogenetics; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2009 |
Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2010 |
Use of chemotherapy for patients with bone and soft-tissue sarcomas.
Topics: Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Dioxoles; Humans; Muscle Neoplasms; Osteosarcoma; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2010 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
Trabectedin therapy for sarcomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2010 |
Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dioxoles; Disease Progression; Health Care Costs; Humans; Kaplan-Meier Estimate; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; United Kingdom | 2010 |
Systemic management strategies for metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lysine; Paclitaxel; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2011 |
Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.
Topics: Animals; Clinical Trials as Topic; Dioxoles; Drug Evaluation; Humans; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2012 |
[Development of multidisciplinary treatment for soft tissue sarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2012 |
Safety and efficacy of ET-743: the French experience.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dioxoles; Disease-Free Survival; Drug Administration Schedule; France; Humans; Infusions, Intravenous; Isoquinolines; Multicenter Studies as Topic; Sarcoma; Survival Analysis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2002 |
ET-743: the US experience in sarcomas of soft tissues.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Humans; Infusions, Intravenous; Isoquinolines; Multicenter Studies as Topic; Sarcoma; Survival Analysis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; United States | 2002 |
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
New therapeutic strategies for soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2003 |
[News of the year 2005 in sarcomas].
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dioxoles; Genetic Markers; Humans; Isoquinolines; Neovascularization, Pathologic; Patient Care Planning; Prognosis; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2006 |
ET-743: a novel agent with activity in soft-tissue sarcomas.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Disease-Free Survival; DNA; DNA Repair; Humans; Models, Chemical; Neoplasm Metastasis; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2006 |
Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dioxoles; Humans; Randomized Controlled Trials as Topic; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Urochordata | 2006 |
Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Evaluation Studies as Topic; Humans; Randomized Controlled Trials as Topic; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2007 |
Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Topics: Animals; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2007 |
[High-dose chemotherapy in soft tissue sarcomas of adults].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dacarbazine; Dioxoles; Dose-Response Relationship, Drug; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Isoquinolines; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2001 |
35 trial(s) available for ecteinascidin 743 and Sarcoma
| Article | Year |
|---|---|
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.
Topics: Adult; Aged; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; France; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Spain; Trabectedin | 2020 |
Quality of life and added value of a tailored palliative care intervention in patients with soft tissue sarcoma undergoing treatment with trabectedin: a multicentre, cluster-randomised trial within the German Interdisciplinary Sarcoma Group (GISG).
Topics: Humans; Palliative Care; Quality of Life; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2020 |
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Humans; Quality of Life; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2021 |
Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liposarcoma, Myxoid; Male; Middle Aged; Neoplasm Staging; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2017 |
A cluster-randomised, controlled proof-of-concept study to explore the feasibility and effect of a patient-directed intervention on quality of life in patients with advanced soft tissue sarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Computers, Handheld; Dioxoles; Feasibility Studies; Female; Humans; Male; Palliative Care; Patient Reported Outcome Measures; Patient Satisfaction; Proof of Concept Study; Quality of Life; Sarcoma; Severity of Illness Index; Tetrahydroisoquinolines; Trabectedin | 2017 |
A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Humans; Middle Aged; Prospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2017 |
Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.
Topics: Antineoplastic Agents, Alkylating; BRCA1 Protein; Female; Genotype; Humans; Male; Predictive Value of Tests; Prospective Studies; Sarcoma; Trabectedin; Treatment Outcome | 2018 |
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Italy; Male; Middle Aged; Osteosarcoma; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Sarcoma; Soft Tissue Neoplasms; Time Factors; Trabectedin | 2018 |
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2013 |
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Ifosfamide; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Translocation, Genetic; Treatment Outcome; Young Adult | 2014 |
Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Dioxoles; DNA; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2014 |
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Drug Therapy, Combination; Female; Gemcitabine; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2015 |
Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Substitution; Female; France; Humans; Infusions, Intravenous; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Young Adult | 2015 |
Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.
Topics: Adult; Dexamethasone; Dioxoles; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2015 |
A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2015 |
Diagnostic use of fluorescence in situ hybridization in expert review in a phase 2 study of trabectedin monotherapy in patients with advanced, translocation-related sarcoma.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dioxoles; Genetic Predisposition to Disease; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Japan; Phenotype; Predictive Value of Tests; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Translocation, Genetic; Treatment Outcome | 2016 |
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; DNA Repair; Doxorubicin; fas Receptor; Female; Humans; Male; Middle Aged; Prognosis; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Tumor Suppressor Protein p53 | 2016 |
Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leiomyosarcoma; Liposarcoma; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2008 |
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Dioxoles; Doxorubicin; Drug Administration Schedule; Female; Humans; Liver; Middle Aged; Nausea; Neutropenia; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Vomiting | 2009 |
Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Compassionate Use Trials; Dioxoles; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Proportional Hazards Models; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2010 |
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dioxoles; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Sarcoma; Soft Tissue Neoplasms; Spain; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2012 |
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Dioxoles; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Failure; Treatment Outcome | 2012 |
A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Algorithms; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Dioxoles; Dose-Response Relationship, Drug; Female; Humans; Male; Medical Oncology; Pediatrics; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Societies, Medical; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2012 |
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Cell Proliferation; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Humans; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2013 |
Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Compassionate Use Trials; Dioxoles; Disease Progression; Female; Global Health; Health Services Accessibility; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Failure; Treatment Outcome; Young Adult | 2013 |
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Topics: Adult; Antineoplastic Agents; Dexamethasone; Dioxoles; Humans; Infusions, Intravenous; Isoquinolines; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neutropenia; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Transaminases | 2002 |
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients.
Topics: Adult; Aged; Biological Availability; Biopsy, Needle; Dioxoles; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasm Staging; Probability; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2004 |
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Isoquinolines; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2004 |
A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Gastrointestinal Neoplasms; Humans; Isoquinolines; Male; Middle Aged; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Failure | 2004 |
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2005 |
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Humans; Isoquinolines; Prospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2005 |
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2005 |
Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Carbon Radioisotopes; Carcinoma, Non-Small-Cell Lung; Dioxoles; Feces; Female; Half-Life; Humans; Isoquinolines; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Sarcoma; Sarcoma, Synovial; Tetrahydroisoquinolines; Trabectedin | 2005 |
Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Female; Humans; Ifosfamide; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; United Kingdom | 2007 |
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dioxoles; Disease Progression; Female; Humans; Isoquinolines; Liver; Male; Middle Aged; Neutropenia; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2001 |
99 other study(ies) available for ecteinascidin 743 and Sarcoma
| Article | Year |
|---|---|
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Kaplan-Meier Estimate; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Sarcoma; Signal Transduction; Soft Tissue Neoplasms; Trabectedin; Tumor Burden; Xenograft Model Antitumor Assays | 2022 |
Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.
Topics: Antibodies, Monoclonal; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2022 |
Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Humans; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Trabectedin and Durvalumab Combination Is Feasible and Active in Relapsing Ovarian Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dioxoles; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results.
Topics: Antineoplastic Agents, Alkylating; Australia; Clinical Trials as Topic; Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2022 |
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Male; Registries; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2023 |
Experience with second-line trabectedin in daily clinical practice: case studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Liposarcoma; Male; Neoplasm Recurrence, Local; Quality of Life; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2022 |
The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety data.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2022 |
Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Neoplasm Recurrence, Local; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells.
Topics: Antineoplastic Agents, Alkylating; Fibrosarcoma; Humans; Leiomyosarcoma; Liposarcoma; Radiation-Sensitizing Agents; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin; Tumor Microenvironment | 2022 |
Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?
Topics: Antineoplastic Agents, Alkylating; Humans; Immune Checkpoint Inhibitors; Sarcoma; Trabectedin | 2023 |
Impact of relative dose intensity of trabectedin with pegfilgrastim support: a single-centre retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Polyethylene Glycols; Retrospective Studies; Sarcoma; Trabectedin | 2023 |
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study.
Topics: Adult; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2023 |
Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Topics: Adult; Antineoplastic Agents, Alkylating; Female; Humans; Liposarcoma, Myxoid; Male; Neoplasm Recurrence, Local; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2023 |
Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2023 |
Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum From the T-Dis Trial.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Female; Histiocytoma, Malignant Fibrous; Humans; Mediastinal Neoplasms; Middle Aged; Prognosis; Retroperitoneal Neoplasms; Sarcoma; Trabectedin | 2019 |
Sarcomas and old age: few options for such a large patient population.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Geriatric Assessment; Humans; Ifosfamide; Male; Prognosis; Sarcoma; Survival Rate; Trabectedin | 2019 |
Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Prognosis; Sarcoma; Survival Rate; Trabectedin | 2019 |
Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Body Height; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Female; Humans; Japan; Male; Middle Aged; Neutropenia; Product Surveillance, Postmarketing; Progression-Free Survival; Retrospective Studies; Rhabdomyolysis; Sarcoma; Soft Tissue Neoplasms; Trabectedin; Young Adult | 2020 |
Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prognosis; Sarcoma; Time-Lapse Imaging; Trabectedin; Young Adult | 2020 |
Novel method for fast trabectedin quantification using hydrophilic interaction liquid chromatography and tandem mass spectrometry for human pharmacokinetic studies.
Topics: Antineoplastic Agents, Alkylating; Chromatography, High Pressure Liquid; Drug Monitoring; High-Throughput Screening Assays; Humans; Hydrophobic and Hydrophilic Interactions; Limit of Detection; Reproducibility of Results; Sarcoma; Tandem Mass Spectrometry; Time Factors; Trabectedin | 2020 |
The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Dacarbazine; Female; Humans; Immune Checkpoint Inhibitors; Mice; Mice, Inbred BALB C; Recombinant Fusion Proteins; Sarcoma; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Clinical Outcome of Systemic Treatment for Advanced Soft Tissue Sarcoma: Real-Life Perspective in Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Female; Furans; Humans; Indazoles; Japan; Kaplan-Meier Estimate; Ketones; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Survival Analysis; Trabectedin; Treatment Outcome | 2020 |
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Cardiovascular Diseases; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dacarbazine; Doxorubicin; Female; Heart; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Product Surveillance, Postmarketing; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Stroke Volume; Trabectedin; Ventricular Function, Left; Young Adult | 2021 |
Trabectedin: useful in leiomyosarcoma and liposarcoma, but less so in other soft tissue sarcomas.
Topics: Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Trabectedin | 2021 |
The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models.
Topics: Animals; Antineoplastic Agents, Alkylating; Disease Models, Animal; Extracellular Matrix; Humans; Sarcoma; Trabectedin; Zebrafish | 2021 |
A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; DNA Damage; DNA Repair; Humans; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2021 |
Establishment and characterization of NCC-ssRMS2-C1: a novel patient-derived cell line of spindle cell/sclerosing rhabdomyosarcoma.
Topics: Adult; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Dactinomycin; Depsipeptides; Gene Fusion; Head and Neck Neoplasms; Humans; Male; Muscle Proteins; Mutation; MyoD Protein; Nuclear Receptor Coactivator 2; Rhabdomyosarcoma; Sarcoma; Trabectedin; Transcription Factors | 2021 |
Analysis of clinical factors associated with survival in patients with soft-tissue sarcoma receiving trabectedin.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Trabectedin; Young Adult | 2021 |
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Dioxoles; DNA Repair; Drug Synergism; Heterografts; Humans; Indoles; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2017 |
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Comparative Genomic Hybridization; Dioxoles; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mice; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |
Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents.
Topics: Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Cycle Checkpoints; Dioxoles; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Furans; Gene Expression Regulation, Neoplastic; Humans; Ketones; Male; Patients; Primary Cell Culture; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2017 |
Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Dioxoles; Female; Humans; Ifosfamide; Male; Middle Aged; Neutropenia; Retrospective Studies; Risk Factors; Sarcoma; Sarcopenia; Tetrahydroisoquinolines; Thinness; Trabectedin | 2018 |
Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma.
Topics: Acetylcysteine; Antineoplastic Agents, Alkylating; Disease-Free Survival; Female; Humans; Liver; Male; Middle Aged; Retrospective Studies; Sarcoma; Trabectedin | 2018 |
TOMAS: revisiting PARP inhibitor combination therapy.
Topics: Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma; Trabectedin | 2018 |
CT-response patterns and the role of CT-textural features in inoperable abdominal/retroperitoneal soft tissue sarcomas treated with trabectedin.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Male; Middle Aged; Peritoneal Neoplasms; Retrospective Studies; Sarcoma; Sensitivity and Specificity; Soft Tissue Neoplasms; Tomography, X-Ray Computed; Trabectedin | 2018 |
Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Retrospective Studies; Sarcoma; Survival Rate; Trabectedin; Young Adult | 2018 |
Cardiotoxicity with trabectedin in the treatment of advanced soft tissue sarcoma.
Topics: Age Factors; Aged, 80 and over; Antineoplastic Agents, Alkylating; Atrial Fibrillation; Cardiotoxicity; Female; Humans; Male; Myocardial Infarction; Pulmonary Edema; Sarcoma; Trabectedin | 2019 |
Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Nuclear Proteins; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2019 |
A decade of change in the treatment of advanced soft tissue sarcoma.
Topics: Antineoplastic Agents; Dioxoles; Drug Design; Humans; Molecular Targeted Therapy; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2013 |
13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome | 2013 |
The intriguing patterns of tumor response to trabectedin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Molecular Targeted Therapy; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Tumor Microenvironment; Uterine Neoplasms | 2013 |
Current questions in soft tissue sarcoma: further steps with Yondelis®.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Humans; Quality of Life; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome | 2013 |
Trabectedin's contribution to the treatment of sarcomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Humans; Molecular Targeted Therapy; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2013 |
Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dioxoles; Disease Progression; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2013 |
The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Austria; Dioxoles; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2013 |
Trabectedin in patients with metastatic soft tissue sarcoma: a retrospective single center analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Male; Middle Aged; Registries; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2013 |
Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Dioxoles; Genotype; Humans; Liver; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Genetic; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2013 |
Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2014 |
Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dioxoles; Disease Progression; Drug Costs; Humans; Indazoles; Probability; Pyrimidines; Quality-Adjusted Life Years; Sarcoma; Spain; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2015 |
Experience with trabectedin in an advanced sarcoma patient on peritoneal dialysis for end-stage renal failure.
Topics: Antineoplastic Agents, Alkylating; Creatinine; Dioxoles; Drug Administration Schedule; Humans; Kidney Failure, Chronic; Male; Middle Aged; Neoplasm Staging; Peritoneal Dialysis; Sarcoma; Tetrahydroisoquinolines; Tomography, X-Ray Computed; Trabectedin | 2013 |
The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chondrosarcoma; Denmark; Dioxoles; Female; Humans; Hyponatremia; Karnofsky Performance Status; Leiomyosarcoma; Liposarcoma; Middle Aged; Multivariate Analysis; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2015 |
Comparison of response evaluation criteria in solid tumours and Choi criteria for response evaluation in patients with advanced soft tissue sarcoma treated with trabectedin: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Drug Administration Schedule; Female; Humans; Image Processing, Computer-Assisted; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Tomography, X-Ray Computed; Trabectedin; Young Adult | 2015 |
BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; BRCA1 Protein; Clinical Trials, Phase II as Topic; Compassionate Use Trials; Dioxoles; Drug Resistance, Neoplasm; Female; Haplotypes; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2015 |
Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Child; Dioxoles; Disease-Free Survival; Female; France; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2015 |
Trabectedin tactics: from sea squirts to sarcomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Female; Humans; Male; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2015 |
Beyond clinical trials in advanced soft tissue sarcoma: what to expect from trabectedin treatment? Foreword.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2015 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contraindications; Dacarbazine; Deoxycytidine; Dioxoles; Female; Femoral Neoplasms; Gemcitabine; Humans; Hysterectomy; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2015 |
Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2015 |
RG7112, a small-molecule inhibitor of MDM2, enhances trabectedin response in soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dioxoles; DNA Damage; Humans; Imidazoles; Imidazolines; Piperazines; Proto-Oncogene Proteins c-mdm2; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Tumor Suppressor Protein p53 | 2015 |
What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease Progression; Female; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2015 |
Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.
Topics: Adult; Dioxoles; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sarcoma; Solitary Fibrous Tumors; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2015 |
Trabectedin is an effective second-line treatment in soft tissue sarcoma patients.
Topics: Dacarbazine; Dioxoles; Disease-Free Survival; Humans; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2015 |
Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Cohort Studies; Dioxoles; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Cross-Over Studies; Dioxoles; Disease Progression; Disease-Free Survival; Drug Substitution; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Randomized Controlled Trials as Topic; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Translocation, Genetic; Treatment Failure; Young Adult | 2016 |
Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dioxoles; Drug Resistance, Neoplasm; Histones; Humans; Hyperthermia, Induced; Models, Biological; Protein Binding; Protein Transport; Proteolysis; Rad51 Recombinase; Recombinational DNA Repair; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
In brief: Two Drugs for soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Furans; Humans; Ketones; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Tubulin Modulators | 2016 |
Heterogeneous and Rare: Toward Histology-Specific Treatment of Soft-Tissue Sarcoma.
Topics: Antineoplastic Agents; Chromosomal Proteins, Non-Histone; Dioxoles; Disease-Free Survival; DNA-Binding Proteins; Furans; Humans; Indazoles; Ketones; Molecular Targeted Therapy; Mutation; Pyrimidines; Sarcoma; SMARCB1 Protein; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Transcription Factors | 2016 |
Complete response after rechallenge with trabectedin in a patient with previously responding high-grade undifferentiated sarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Neoplasm Grading; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Trabectedin in Soft Tissue Sarcoma: Have We Hit the Bull's-eye?
Topics: Dioxoles; Humans; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Trabectedin for sarcomas in daily clinical practice: analysis of 45 patients treated in a French institution.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; France; Humans; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Cell Survival; Cells, Cultured; Cockayne Syndrome; Cysteine Proteinase Inhibitors; Dioxoles; DNA Damage; DNA Helicases; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Fibroblasts; Genetic Complementation Test; Humans; Leupeptins; Neoplasms; Phosphorylation; Poly-ADP-Ribose Binding Proteins; RNA Polymerase II; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; von Hippel-Lindau Disease; Von Hippel-Lindau Tumor Suppressor Protein; Xeroderma Pigmentosum; Xeroderma Pigmentosum Group D Protein | 2008 |
[Recommendations for diagnostic and therapeutic management of soft tissue sarcoma].
Topics: Antineoplastic Agents; Dioxoles; France; Humans; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2009 |
Trabectedin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Humans; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2009 |
Trabectedin: new drug. Soft-tissue sarcomas: too many adverse effects.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Drug Approval; Europe; Humans; Orphan Drug Production; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2009 |
The use of positron emission tomography in soft tissue sarcoma patients under therapy with trabectedin.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Positron-Emission Tomography; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome | 2009 |
Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Alkylating; Chemical and Drug Induced Liver Injury; Dioxoles; Fatal Outcome; Humans; Liver Failure, Acute; Male; Neoplasms, Radiation-Induced; Sarcoma; Skull Base Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2010 |
Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information.
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dioxoles; Humans; Markov Chains; Models, Statistical; Neoplasm Metastasis; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2011 |
Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Urochordata; Young Adult | 2010 |
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Base Sequence; Cell Line, Transformed; Dioxoles; DNA Primers; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Flow Cytometry; Genes, BRCA1; Humans; Male; Middle Aged; Nuclear Proteins; Polymorphism, Single Nucleotide; Recombination, Genetic; RNA, Messenger; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Transcription Factors | 2011 |
Trabectedin in the treatment of metastatic soft-tissue sarcoma: cost-effectiveness and cost-utility are yet to be proved.
Topics: Antineoplastic Agents, Alkylating; Cost-Benefit Analysis; Dioxoles; Humans; Neoplasm Metastasis; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2011 |
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
Topics: Antineoplastic Agents, Alkylating; BRCA1 Protein; Dioxoles; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Nuclear Proteins; Recombination, Genetic; Retrospective Studies; RNA, Messenger; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Transcription Factors; Treatment Outcome | 2011 |
Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Line, Tumor; Child; DAX-1 Orphan Nuclear Receptor; Dioxoles; Europe; Gene Expression Regulation, Neoplastic; Humans; Oncogene Proteins, Fusion; Promoter Regions, Genetic; Proto-Oncogene Protein c-fli-1; RNA-Binding Protein EWS; RNA-Binding Protein FUS; Sarcoma; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Transcription Factor CHOP | 2011 |
Role of palliative chemotherapy in advanced epithelioid sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Palliative Care; Prognosis; Prospective Studies; Retrospective Studies; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2012 |
[Trabectedin registry].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Czech Republic; Dioxoles; Humans; Middle Aged; Registries; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2011 |
Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option.
Topics: Ambulatory Care; Antineoplastic Agents, Alkylating; Dioxoles; Drug Administration Schedule; Female; Humans; Infusion Pumps, Implantable; Infusions, Intravenous; Male; Middle Aged; Palliative Care; Patient Satisfaction; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2012 |
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Translocation, Genetic; Treatment Outcome; Young Adult | 2012 |
Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Compassionate Use Trials; Dioxoles; Female; France; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2013 |
Sea squirt assaults sarcomas.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dioxoles; Humans; Isoquinolines; Neoplasm Recurrence, Local; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Urochordata | 2002 |
Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations.
Topics: Actins; Antineoplastic Agents, Alkylating; Ascorbic Acid; Biological Transport; Cell Adhesion; Cell Movement; Collagen; Dioxoles; Drug Resistance, Neoplasm; Humans; Isoquinolines; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured | 2003 |
Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Dioxoles; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Isoquinolines; Kinetics; Mutation; Oligonucleotide Array Sequence Analysis; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2005 |
Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas?
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dioxoles; Humans; Isoquinolines; Research Design; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2005 |
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Dioxoles; Disease-Free Survival; Female; Humans; Liver Diseases; Male; Middle Aged; Premedication; Sarcoma; Steroids; Tetrahydroisoquinolines; Trabectedin | 2006 |
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
Topics: Cell Proliferation; Dioxoles; Doxorubicin; Humans; Karyotyping; Mutation; RNA, Small Interfering; Sarcoma; Sensitivity and Specificity; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2007 |
New therapeutics for soft-tissue sarcomas in adults.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Dioxoles; Enzyme Inhibitors; Humans; Protein Kinases; Protein-Tyrosine Kinases; Sarcoma; Sirolimus; Tetrahydroisoquinolines; Thalidomide; TOR Serine-Threonine Kinases; Trabectedin; Vascular Endothelial Growth Factor A | 2007 |
Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Fatal Outcome; Humans; Male; Middle Aged; Rhabdomyolysis; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2007 |
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Cycle; Cell Survival; Dioxoles; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Inhibitory Concentration 50; Isoquinolines; Methotrexate; Proto-Oncogene Proteins c-bcl-2; Retinoblastoma Protein; Sarcoma; Sensitivity and Specificity; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Dioxoles; Doxorubicin; Drug Synergism; Flow Cytometry; Humans; Inhibitory Concentration 50; Isoquinolines; Microscopy, Fluorescence; Paclitaxel; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Trimetrexate; Tumor Cells, Cultured | 2001 |